HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer

Journal of Clinical Oncology

Volumn 18, Issue 20, 2000, Pages 3471-3479

  Berry, Donald A ^a   Muss, Hyman B ^a   Thor, Ann D ^a   Dressler, Lynn ^a   Liu, Edison T ^a   Broadwater, Gloria ^a   Budman, Dan R ^a   Henderson, I Craig ^a   Barcos, Maurice ^a   Hayes, Daniel ^a   Norton, Larry ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; ONCOPROTEIN; PROTEIN P53; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; ONCOGENE NEU; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK;

EID: 0034667952     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.20.3471     Document Type: Article

References (23)

1. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
2. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
3. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
4. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells
5. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer
6. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer
7. Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
8. Relation of oestradiol-mediated growth stimulation with the expression of c-erbB-2 protein in xenotransplanted oestradiol-receptor-positive and -negative breast carcinomas
9. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
10. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein
11. Her-2/c-erbB2 (HER-2) overexpression is a biomarker of tamoxifen resistance in breast cancer
12. ERBB2 expression and benefit from 5 versus 2 years of adjuvant tamoxifen for postmenopausal stage II breast cancer patients
13. Overexpression of c-erbB-2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
14. Variation of hormonal receptor pS2 c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: A study of 74 cases
15. pS2 Protein: A marker improving prediction of response to neoadjuvant tamoxifen in postmenopausal breast cancer patients
16. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study
17. A tumor marker utility grading system (TMUGS): A framework to evaluate clinical utility of tumor markers
18. Dose and dose intensity trial of adjuvant chemotherapy for stage II, node positive breast carcinoma: Initial results of CALGB 8541
19. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer
20. c-erbB-2 Expression predicts response to adjuvant therapy in women with node positive early breast cancer
21. erbB-2, p53 and efficacy of adjuvant therapy in lymph node-positive breast cancer
22. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
23. Categorical Data Analysis